Decreased transfusion with luspatercept in patients with TDT was associated with increased erythropoietic markers and decreasing hepcidin. Furthermore, s‐ferritin reduction associated with increased erythroid iron incorporation (marked by sTfR1) allowed increased erythrocyte marrow output, consequently reducing transfusion needs and enhancing rerouting of hemolysis (heme) iron and non‐transferrin‐bound iron to the liver. LIC increased in patients with intact spleens, consistent with iron redistribution given the hepcidin reduction.
- Badges
- Science topic
- Similar topics
- Computer Science
- Program
More Wajeeha Hussain's questions See All
Similar questions and discussions